Augmentation of DNA vaccine potency through secretory heat shock protein-mediated antigen targeting.
In an effort to enhance the potency of DNA vaccines, we have developed a new strategy to increase antigen presentation by dendritic cells, one that results in markedly improved cytotoxic T-lymphocyte responses, antibody production, and antitumor effects in vivo. Here, we present the rationale and design of a vaccine encoding a secreted antigen-heat shock protein 70 fusion molecule, targeted to the MHC class I cross-presentation pathway of dendritic cells. Using the human papilloma virus 16 E7 protein as a model antigen, we illustrate the preparation of this vaccine and the main experimental procedures used to test such constructs.
D000914:Antibodies, Viral / Q000276:immunology; D017951:Antigen Presentation; D000941:Antigens / Q000235:genetics / Q000276:immunology; D001483:Base Sequence; D003001:Cloning, Molecular; D018840:HSP70 Heat-Shock Proteins / Q000096:biosynthesis / Q000235:genetics*; D006801:Humans; D008969:Molecular Sequence Data; D009856:Oncogene Proteins, Viral / Q000235:genetics / Q000276:immunology; D050725:Papillomavirus E7 Proteins; D011993:Recombinant Fusion Proteins / Q000276:immunology; D014412:Tumor Virus Infections / Q000276:immunology; D019444:Vaccines, DNA / Q000235:genetics* / Q000276:immunology*
D000914:Antibodies, Viral; D000941:Antigens; D018840:HSP70 Heat-Shock Proteins; D009856:Oncogene Proteins, Viral; D050725:Papillomavirus E7 Proteins; D011993:Recombinant Fusion Proteins; D019444:Vaccines, DNA; C059731:oncogene protein E7, Human papillomavirus type 16